Drug Monitoring of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Phase 2 Study of Measurement of Trough Levels of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01078311

Acronym

DOSE-HEP

Enrollment

100

Registered

2010-03-02

Start date

2010-02-28

Completion date

2014-02-28

Last updated

2010-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Cancer

Keywords

Patients with advanced hepatocellular cancer

Brief summary

Sorafenib improves overall survival and progression free survival in advanced hepatocellular carcinoma. Wide interindividual pharmacokinetic variability was observed. Data from early phase trials in solid tumours showed trough sorafenib levels were associated with incidence of skin rash and hypertension. Rash, hypertension and higher trough levels were moderately predictive of progression free survival.The trough level of sorafenib may be predictive of survival and response in patients treated with sorafenib for advanced hepatocellular carcinoma.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ECOG ≤ 2 * Histologically or cytologically diagnosed hepatocellular carcinoma, or diagnosis on at least one cross-sectional imaging with the characteristic appearance of HCC (i.e. liver lesion with arterial enhancement and portal venous washout) * Decision to treat with single agent sorafenib at 400mg bid (dose reductions or interruptions are permitted if side effects occur during treatment) * No prior systemic chemotherapy or targeted therapy * Child-Pugh liver function class A or B * At least one untreated target lesion that can be measured in one dimension according to RECIST * Adequate organ functions

Exclusion criteria

* Prior systemic chemotherapy or molecularly targeted therapy * Concurrent active malignancy * Concomitant strong CYP3A4 induced or inhibitor at a therapeutic dose (see section 6.4.1) * Medical or psychiatric conditions that compromise the patient's ability to give informed consent * Hypertension that cannot be controlled by medications (\> 150/100 mmHg despite optimal medical therapy) * History of, or known brain metastases (skull metastases allowed), carcinomatous meningitis, or leptomenigeal disease * Major surgery (e.g. open abdominal therapy, pelvic, thoracic, orthopaedic or neurosurgery) within 4 weeks of the date of first dose * Local-regional treatment (i.e. percutaneous and trans-arterial procedures) within 4 weeks. Restaging CT or MRI scan must be repeated at least 4 weeks after local-regional treatment and within 3 weeks before the date of first dose * For patients treated with Yttrium (90Y) radiotherapy, a washout period of 2 months is required. * Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol * Pregnancy or breast feeding

Design outcomes

Primary

Measure	Time frame
To demonstrate the correlation of trough sorafenib level with overall survival in advanced hepatocellular carcinoma	4 years

Secondary

Measure	Time frame
To correlate trough sorafenib level with progression free survival	4 years
To correlate trough sorafenib level with response (disease-control vs progressive disease) by RECIST criteria	4 years
To correlate trough sorafenib level with alpha fetoprotein (AFP) response	4 years
To correlate trough sorafenib level with side effects (rash and hypertension)	4 years

Countries

Australia

Contacts

Primary ContactMark Wong, MBBS, FRACP

Mark.Wong@swahs.health.nsw.gov.au61298455200

Outcome results